A new study led by Prof. Tan Zhiliang from the Institute of Subtropical Agriculture of the Chinese Academy of Sciences has ...
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...